C12N 2740/16022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 341 US grants and 387 published applications in this corpus.
Search patents in C12N- Granted patents
- 341
- Published applications
- 387
- Assignees
- 303
- Inventors
- 857
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 5 | 0 |
| 1995 | 6 | 0 |
| 1996 | 7 | 0 |
| 1997 | 21 | 0 |
| 1998 | 19 | 0 |
| 1999 | 16 | 0 |
| 2000 | 19 | 0 |
| 2001 | 8 | 3 |
| 2002 | 9 | 12 |
| 2003 | 13 | 18 |
| 2004 | 2 | 9 |
| 2005 | 6 | 14 |
| 2006 | 5 | 12 |
| 2007 | 6 | 8 |
| 2008 | 4 | 10 |
| 2009 | 5 | 8 |
| 2010 | 10 | 14 |
| 2011 | 6 | 6 |
| 2012 | 10 | 10 |
| 2013 | 2 | 12 |
| 2014 | 8 | 7 |
| 2015 | 13 | 14 |
| 2016 | 3 | 30 |
| 2017 | 13 | 14 |
| 2018 | 16 | 18 |
| 2019 | 15 | 23 |
| 2020 | 18 | 14 |
| 2021 | 15 | 23 |
| 2022 | 10 | 18 |
| 2023 | 5 | 22 |
| 2024 | 14 | 25 |
| 2025 | 9 | 24 |
| 2026 | 10 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Non-viral transgenesis15 Sep 2026US 12,735,719 B2The Regents of the University of California
- Nucleic acid molecules and dual-functional peptides having antiviral activity and delivery activity, compositions and methods thereof12 May 2026US 12,624,368 B2The University of Hong Kong
- Live imaging system to visualize the retro-transcribed viral DNA genome28 Apr 2026US 12,613,239 B2Institut Pasteur
- Modified immunogenic proteins10 Mar 2026US 12,569,551 B2International AIDS Vaccine Initiative
- Ferritin nanoparticle displaying an HIV trimer10 Mar 2026US 12,570,701 B2International AIDS Vaccine Initiative
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- Lentiviral System17 Sep 2026US 2026/0275376 A1Expression Therapeutics LLC
- Target protein expression platform using viral nucleocapsid10 Sep 2026US 2026/0265307 A1University-Industry Foundation, Yonsei University
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Modified immunogenic proteins6 Aug 2026US 2026/0224689 A1International AIDS Vaccine Initiative
Most cited
By later US patents
- Vector and method of use for nucleic acid delivery to non-dividing cells323US 6,013,516 AThe Salk Institute for Biological Studies · 2000
- Generation and selection of novel DNA-binding proteins and polypeptides293US 5,096,815 AProtein Engineering Corporation · 1992
- Method and means for producing high titer, safe, recombinant lentivirus vectors261US 5,994,136 ACell Genesys, Inc. · 1999
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Generation and selection of novel DNA-binding proteins and polypeptides254US 5,198,346 AProtein Engineering Corporation · 1993